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Abstract
Background: Several studies have shown that the antimuscarinic treatment of overactive bladder is characterized
by low long-term persistence rates. We have investigated the persistence of solifenacin in real life by means of
telephonic interviews in a prospective cohort. We included both patients with idiopathic overactive bladder as well
as neurogenic overactive bladder.
Methods: From June 2009 until July 2012 patients with idiopathic or neurogenic overactive bladder who were
newly prescribed solifenacin were included. In total 123 subjects were followed prospectively during one year by
means of four telephonic interviews, which included questions about medication use and adverse events.
Results: After one year 40% of all patients included was still using solifenacin, 50% discontinued and 10% was lost
to follow-up. In the neurogenic group 58% was still using solifenacin versus 32% in the idiopathic group after one
year (p < 0,05). The main reasons to stop solifenacin were lack of efficacy, side effects and a combination of both.
Conclusions: This prospective cohort study showed a real life continuation rate of 40% after 12 months. This
continuation rate is higher than found in most other studies.
The use of regular telephonic evaluation might have improved medication persistence. The findings of this study
also suggest that patients with neurogenic overactive bladder have a better persistence with this method of
evaluation compared to patients with idiopathic overactive bladder.
Trial registration: This study was retrospectively registered on march 17, 2017 at the ISRCTN registry with study ID
ISRCTN13129226.
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Background
Antimuscarinics are the first-line therapy in the treat-
ment of overactive bladder (OAB). This applies to idio-
pathic OAB (iOAB) as well as neurogenic OAB (nOAB).
The use of antimuscarinics in patients with iOAB is
characterized by very low persistence rates. Results from
short-term studies show discontinuation rates ranging
from 4 to 31% [1]. The long-term persistence to
antimuscarinics in OAB is not well investigated. A sys-
tematic review conducted by Veenboer et al. found
that persistence beyond 1 year rarely exceeded 10% of
the patients [2]. These data might even represent an
overestimation of the persistence because reviews of
medical claims data show much higher discontinuation
rates (up to 83% within the first 30 days) [1]. Furthermore,
patients who have collected the prescribed medications
might not use them because of other reasons, like fear for
adverse effects.* Correspondence: mtijn@hotmail.com
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Regarding the use of antimuscarinics in the treatment
of nOAB much less studies have been performed com-
pared to iOAB. Patients with nOAB are a heterogeneous
group with different underlying neurologic conditions,
such as multiple sclerosis, spinal cord injury, Parkinson
disease, cerebral palsy and meningomyelocele [3]. Pa-
tients often suffer from incontinence, urgency, frequency
or impaired bladder emptying. It has been shown that
the use of antimuscarinics in this group is associated
with better patient-reported cure/improvement com-
pared to placebo. However, there is a higher incidence of
adverse events [4].
This prospective study was carried out to investigate
the persistence rate in real life among patients with idio-
pathic or neurogenic OAB who were prescribed solifena-
cin. We followed them during one year by means of
telephonic interviews.
Furthermore, we wanted to investigate the reasons
why patients stopped taking their medications. Third, we
wanted to investigate if we could find any differences be-
tween patients with idiopathic OAB versus neurogenic
OAB.
Methods
This study was undertaken at the urology department of
the Erasmus University Medical Center, Rotterdam, The
Netherlands. The ethics committee of the hospital ap-
proved the study protocol. The inclusion was carried out
from June 2009 until July 2012. After giving informed
consent, patients older than 18 years and newly pre-
scribed solifenacin because of complaints of idiopathic
or neurogenic OAB, were included. Solifenacin, under
the trade name Vesicare, is a urinary antispasmodic of
the anticholinergic class. It is produced by Astellas
Pharma BV. It is available in 5 and 10 mg. The starting
dose was chosen by the doctor who prescribed the soli-
fenacin but could be adjusted during the study period.
Because this observational study investigated the persist-
ence rate in real life in patients who had been prescribed
solifenacin by their own doctor, they had to collect the
solifenacin themselves at a pharmacy of choice.
Patients who had used anticholinergic drugs less than
7 days before they started solifenacin were excluded.
Participants were allowed to continue possible other
urologic medications, for example alfa-blockers, but not
other anticholinergic drugs.
Telephonic surveys were taken at 1, 3, 6 and 12 months
after starting solifenacin. The patients were asked whether
they were continuing the medication. They were also inter-
viewed about possible side effects and if they had discontin-
ued the therapy, what had been reasons for stopping.
Statistical analysis was performed using SPSS statistical
software. The Chi-square test was used to evaluate the
differences between groups.
Results
During the study period a total number of 123 patients
were included in this study. Twelve patients were lost to
follow-up. Table 1 displays the demographic characteris-
tics. Eighty-three patients received solifenacin because of
idiopathic OAB and 40 patients because of neurogenic
OAB. Among this group 17 patients had a spinal cord
injury, 10 multiple sclerosis. The rest was diagnosed with
other conditions as you can find in Fig. 1.
After one year 40% of all patients included were still
using solifenacin, 50% discontinued and 10% was lost to
follow-up. Table 2 shows the persistence rate after one
year in patients with idiopathic OAB and neurogenic
OAB. Persistence in the neurogenic group was 58% ver-
sus 32% in the idiopathic group (p < 0,05).
The main reasons to stop taking solifenacin were lack
of efficacy (39%), side effects (30%) and a combination of
both (13%).
Of the total group of 111 interviewed patients 64 pa-
tients (58%) experienced side effects within one year.
Most common side effects were dry mouth, constipation,
blurred vision, dry eyes and abdominal pain.
Discussion
Antimuscarinic drugs have been available for many years
for the treatment of OAB.
OAB is a chronic condition and long-term effective treat-
ment might be of importance for the quality of life. Unfor-
tunately, adherence and persistence to antimuscarinics are
poor. OAB medication is known to have the lowest persist-
ence in comparison to other chronic oral medication like
cardiovascular, antidiabetic and osteoporosis treatments [5].
Table 1 Demographics
Characteristic Patients included
Age: years
Mean (S.D.) 61.7 (15.4)
Range 20.1 – 90.2
Gender: no (%)
Men 70 (57%)
Women 53 (43%)
Starting dose : no (%)
10 mg/day 12 (9.8)
5 mg/day 106 (86.2)
5 mg/2 days 3 (2.4)
2.5 mg/2 days 1 (0.8)
unknown 1 (0.8)
Condition: no (%)
Idiopathic OAB 83 (67.5)
Neurogenic OAB 40 (32.5)
S.D. Standard deviation
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Regarding the use of benign prostate hyperplasia (BPH)
medication, a large population-based cohort study using an
administrative prescription database showed that the per-
sistence was 29% after one year [6].
Doses of solifenacin succinate (5 mg and 10 mg) once
daily (OD) have proven to be effective [7–9]. Haab et al.
showed that 81% of the patients completed 40 weeks of
open-label treatment with only 4,7% discontinuation be-
cause of adverse events [10]. Clinical and prescription
database studies demonstrated much lower continuation
rates varying from 9 to 35%. [11–15].
In our study we found a continuation rate of 40% after
12 months. This continuation rate is higher than found
in most other studies. We think that this difference
might be explained by the fact that the patients received
telephonic interviews regularly. This is somewhat in line
with other studies, which suggest that compliance to
OAB therapy improves with patient education about
OAB en its treatment [16, 17].
Furthermore, an additional difference in our study was
the possibility of adjusting the medication dose during
the study period. Patients who complained about side ef-
fects could receive a lower dose, whereas people who
had little effect could receive a higher dose. This possible
adjustment might have contributed to a higher persist-
ence. This observation might encourage other caregivers
to evaluate regularly patients who receive antimuscarinic
medication for OAB.
A possible tool for the future is the use of Short
Message Service (SMS) to improve utilization of and
adherence to anticholinergic medication. It is a simple
and inexpensive strategy, which has proven to help
patients taking their medications on time [18]. Fur-
thermore, it has been used to increase medication ad-
herence to a variety of medication classes on a short
term [19–22]. This tool could educate people with
OAB and help them to improve persistence with anti-
muscarinic medication on the long term.
A large screening survey performed in the USA to
identify patient-reported reasons for discontinuing
overactive bladder medication found that the most
mentioned reasons were: “didn’t work as expected”,”
switched to new medication”, “learned to get by with-
out medication” and “I had side effects” [23].
These reported reasons are similar to our study were
the main reasons to stop taking the medications were
lack of efficacy (39%), side effects (30%) and a combin-
ation of both (13%). A possible confounder of our study
is that Dutch patients usually have to pay a part of the
medication costs themselves when the product is still
patented. No one reported these costs as a reason to
stop, but we did not ask explicitly.
As mentioned before, antimuscarinic treatment in pa-
tients with neurogenic OAB has not been thoroughly
evaluated. Treatment for neurogenic OAB is important
in order to provide more bladder control, decrease urin-
ary incontinence and, therefore, decrease the risk of de-
cubitus ulcers, prevent UTI’s and ultimately to preserve
renal function [24]. Antimuscarinics are advised to use
Fig. 1 Patient distribution neurogenic OAB
Table 2 Persistence rate solifenacin after one year
Patients still using Patients discontinued Lost to FU
All patients 50 (40.7%) 61 (49.6%) 12 (9.7%)
Neurogenic OAB 23 (57.5%) 13 (32.5%) 4 (10%)
Idiopathic OAB 27 (32.5%) 48 (57.8%) 8 (9.7%)
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as a first line medical treatment, but data on persistence
in nOAB are lacking [25]. A study on the epidemiology
and healthcare utilization of neurogenic bladder patients
performed in the US found that 71, 5% was using one of
more OAB drugs during the study period of one year.
Only 29% of the patients continued that therapy. An-
other 38% of the patients stopped and did not restart,
34% stopped and restarted [24]. This suggests that
neurogenic bladder patients are not adequately managed.
In our study 32% of the patients with neurogenic OAB
discontinued versus 58% of the patients with idiopathic
OAB, which was a significant difference. This suggests
that patients with neurogenic OAB have a better persist-
ence compared to patients with idiopathic OAB.
Conclusions
This prospective cohort study showed a real life continu-
ation rate of solifenacin of 40% after 12 months. This
continuation rate is higher than found in most other
studies.
The use of regular telephonic evaluation might have
improved medication persistence. This observation
should be further investigated. The findings of this study
also suggest that patients with neurogenic overactive
bladder have a better persistence with this method of
evaluation compared to patients with idiopathic over-
active bladder.
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